Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010


Delayed Quote. Delayed Nasdaq - 11/30 04:00:00 pm
208.63 USD   +7.56%
11/30India's Serum Institute delivers first Novavax shot through COVAX
11/30INSIDER SELL : Novavax
11/30Experimental Hipra vaccine could help combat variants, says minister
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Glancy Prongay & Murray LLP : a Leading Securities Fraud Law Firm, Announces Investigation of Novavax, Inc. (NVAX) on Behalf of Investors

10/21/2021 | 07:26pm EST

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) investors concerning the Company’s possible violations of the federal securities laws.

If you suffered a loss on your Novavax investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/novavax-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On October 19, 2021 Politico reported that, while “Novavax recently attested to some of its [vaccine] analytics and testing issues in a quarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood.” According to Politico, two people “with direct knowledge of the matter” claim Novavax “has struggled to attain anywhere close” to the 90 percent vaccine purity levels required to meet Food and Drug Administration guidance. The report continues, “[a]nother person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent” and that “[l]ow purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.”

On this news, Novavax’s share price fell $23.69, or almost 15%, to close at $136.86 per share on October 20, 2021, thereby injuring investors.

Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice: Persons with non-public information regarding Novavax should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.

About GPM

Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM’s lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM’s attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

© Business Wire 2021
All news about NOVAVAX, INC.
11/30India's Serum Institute delivers first Novavax shot through COVAX
11/30INSIDER SELL : Novavax
11/30Experimental Hipra vaccine could help combat variants, says minister
11/29WALL STREET STOCK EXCHANGE : Back to the guessing game
11/26Novavax developing vaccine that targets new COVID-19 variant
11/26Novavax testing vaccine that targets new COVID-19 variant
11/26Novavax Inc - Has Already Initiated Development Of A New Recombinant Spike Protein Base..
11/26Novavax - recent data from phase 2 trial lead us to believe that our vaccine is likely ..
11/26Novavax - will have new recombinant spike protein based on known genetic sequence of b...
11/26Novavax statement on nu variant
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2021 1 396 M - -
Net income 2021 -905 M - -
Net cash 2021 756 M - -
P/E ratio 2021 -17,2x
Yield 2021 -
Capitalization 15 774 M 15 774 M -
EV / Sales 2021 10,8x
EV / Sales 2022 2,86x
Nbr of Employees 792
Free-Float 98,5%
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 208,63 $
Average target price 260,60 $
Spread / Average Target 24,9%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.87.10%15 774
MODERNA, INC.237.35%142 893
LONZA GROUP AG30.63%59 859
SEAGEN INC.-8.64%29 257
CELLTRION, INC.-42.34%23 827